Please login to the form below

Not currently logged in


This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

AZ’s MYSTIC survival data is in – and it’s a bust

AZ’s MYSTIC survival data is in – and it’s a bust

There’s no doubt that overall the study is a big disappointment, and will allow Merck &Co’s rival PD-1 inhibitor Keytruda (pembrolizumab) to maintain its fierce grip on the

Latest news

More from news
Approximately 361 fully matching, plus 1,092 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The deal between Merck &Co and Samsung Bioepis has been in place since 2013, when Merck &Co began to work with Samsung Bioepis to produce biosimilars. ... Merck &Co has paid $155m to Samsung Bioepis to cover the investments made so far, plus interest, in

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Update: Ewan  Barbour, Market Access and Pricing Director at Merck will also be speaking at the event.

  • Tackling a formidable foe Tackling a formidable foe

    Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis. " /. ... Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck.

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and

More from intelligence
Approximately 8 fully matching, plus 118 partially matching documents found.

Latest appointments

More from appointments
Approximately 38 fully matching, plus 135 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 70 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....